Immix Biopharma shares are trading higher after the company announced NXC-201 clinical results showed 100% overall response rate in DARZALEX-relapsed or refractory AL amyloidosis with zero ICANs in the ongoing NEXICART-1 Phase 1b/2a trial.
Portfolio Pulse from Benzinga Newsdesk
Immix Biopharma announced positive clinical results for NXC-201, showing a 100% overall response rate in DARZALEX-relapsed or refractory AL amyloidosis patients in the ongoing NEXICART-1 Phase 1b/2a trial.

May 22, 2023 | 12:29 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Immix Biopharma shares are trading higher after positive NXC-201 clinical results in the NEXICART-1 Phase 1b/2a trial.
Immix Biopharma's positive clinical results for NXC-201 in the NEXICART-1 Phase 1b/2a trial indicate a potential breakthrough in treating DARZALEX-relapsed or refractory AL amyloidosis patients. This news is highly relevant and important for investors, as it demonstrates the company's progress in developing effective treatments. The positive results are likely to drive the stock price higher in the short term, as investors react to the promising data.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100